

23<sup>rd</sup> February, 2026

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Limited  
Exchange Plaza, C-1,  
Block- G, Bandra – Kurla Complex,  
Bandra (East), Mumbai – 400051  
**Symbol: AAKAAR**

Dear Sir/ Madam,

Ref.: Disclosure under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 (“SEBI Regulations”)

Pursuant to Regulation 30(4)(i)(d) read with Schedule III of SEBI [Listing Obligations and Disclosure Requirements], Regulations 2015, we hereby submit the details as required under Para B, Clause 2(a) of Part A of Schedule III of the said Regulations of the SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

The above details required under Regulation 30 of SEBI Listing regulations are provided in Annexure I.

Thanking you,

Yours truly,  
For Aakaar Medical Technologies Ltd.

Anoopkumar V. Pillai  
Company Secretary & Compliance Officer

Encl: as above.

**Annexure I**

1	Name of the entity(ies) with whom agreement/JV is signed	Xelix Partner Clinic Platform – A strategic clinic partnership and network expansion initiative under Xelix Clinics (a healthcare delivery vertical promoted by Aakaar Medical Technologies Limited). Individual agreements will be executed with independent dermatology, hair, skin, and aesthetic clinics across India under the “Xelix Partner Clinic” model.
2	Area of Agreement/ JV	India
3	Domestic/ International	Domestic
4	Share exchange ratio/JV ratio	Not Applicable.
5	Scope of Business operation of agreement/ JV	The agreement provides for: <ul style="list-style-type: none"> <li>• Onboarding of independent dermatology, hair, skin, and aesthetic clinics under the Xelix Partner Clinic Platform.</li> <li>• Standardization of clinical protocols in hair restoration, regenerative aesthetics, injectables, peels, and device-based procedures.</li> <li>• Access to Aakaar’s proprietary and licensed portfolio including dermal fillers, toxin, regenerative products, and advanced cosmeceuticals.</li> <li>• Digital Marketing, Performance marketing, Lead Generation, Branding support, marketing collateral, digital presence support, and CRM integration.</li> <li>• Clinical training, SOP standardization, and compliance alignment.</li> <li>• Data-driven performance analytics and business optimization support.</li> </ul> The objective is to create a scalable, asset-light, pan-India specialty clinic network.
6	Details of consideration paid/ received in agreement/ JV	The structure is primarily commercial and operational in nature. Revenue streams may include: <ul style="list-style-type: none"> <li>• Product supply margins</li> <li>• Platform fee or onboarding fee, where applicable</li> <li>• Revenue sharing on procedures</li> <li>• Marketing and technology support fees where applicable</li> </ul> No material upfront capital acquisition is involved in the base partnership model. The structure remains asset-light with limited

		capital expenditure.
7	Significant terms and conditions of agreement/ JV in brief	<ul style="list-style-type: none"> <li>• Defined territory and non-compete clauses, where applicable.</li> <li>• Optional adoption of approved treatment protocols and product portfolio.</li> <li>• Branding under the Xelix Partner Clinic identity while retaining local ownership.</li> <li>• Compliance with regulatory, ethical, and quality standards.</li> <li>• Periodic performance review and minimum business commitment thresholds.</li> <li>• Defined tenure with renewal clauses subject to performance benchmarks.</li> </ul>
8	Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	No
9	Size of the entity(ies)	The platform is designed to onboard High Networth to Aakaar Revenue specialty dermatology and aesthetic clinics with annual revenues as per Aakaar Medical Technologies Limited Criteria at the time of onboarding, with scalability potential post integration into the Xelix ecosystem. The platform targets structured expansion across Tier 1, Tier 2, and emerging Tier 3 cities.
10	Rationale and benefit expected	<ul style="list-style-type: none"> <li>• Creation of a scalable specialty clinic network without heavy capex.</li> <li>• Strengthening downstream demand for Aakaar’s product portfolio.</li> <li>• Recurring revenue visibility through integrated product and service model.</li> <li>• Enhanced brand equity in the dermatology and aesthetic segment.</li> <li>• Data-driven expansion model with predictable ROI.</li> <li>• Improved market penetration for high-margin injectables and regenerative products.</li> </ul> <p>The platform aligns with the long-term strategy to integrate product distribution with clinical delivery infrastructure</p>
11	Any other information relevant to be shared	The Xelix Partner Clinic Platform

		<p>represents a strategic shift toward vertical integration in the dermatology and aesthetic ecosystem. The initiative is expected to improve margin profile, enhance brand stickiness, and build a defensible clinical network aligned with long-term growth strategy. Rollout will be phased and performance-led, ensuring capital efficiency and risk control.</p>
--	--	---

*Disclaimer: This intimation is being made for information purposes only and does not constitute an offer, invitation, or commitment to enter into any binding arrangement, and the proposed strategic tie-up remains subject to execution of definitive agreements and applicable regulatory approvals, as applicable.*